Real world COPD: Association of morning symptoms with clinical and patient reported outcomes

COPD: Journal of Chronic Obstructive Pulmonary Disease

Volumn 10, Issue 6, 2013, Pages 679-686

  Roche, Nicolas ^a   Small, Mark ^b   Broomfield, Sarah ^b   Higgins, Victoria ^b   Pollard, Ryan ^b  

^a Institut Cochin   (France)

^b ADELPHI REAL WORLD   (United Kingdom)

Author keywords

CAT score; Daily activity; Exacerbations; Morning symptoms; Symptom variability

Indexed keywords

ANTIINFLAMMATORY AGENT; BRONCHODILATING AGENT;

ADULT; AGED; ARTICLE; BODY MASS; BRONCHOSPASM; CHEST TIGHTNESS; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMORBIDITY; COUGHING; DAILY LIFE ACTIVITY; DISEASE EXACERBATION; DISEASE SEVERITY; DYSPNEA; EMPLOYMENT; EXERCISE; FEMALE; HEALTH CARE PERSONNEL; HEALTH STATUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MORNING SYMPTOM; PRIORITY JOURNAL; SMOKING; SPUTUM; SYMPTOM; WHEEZING;

ABSENTEEISM; ACTIVITIES OF DAILY LIVING; AGE FACTORS; AGED; BODY MASS INDEX; CIRCADIAN RHYTHM; COST OF ILLNESS; EUROPE; FEMALE; FORCED EXPIRATORY VOLUME; HEALTH STATUS; HUMANS; MALE; MIDDLE AGED; PATIENT COMPLIANCE; PATIENT OUTCOME ASSESSMENT; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SEVERITY OF ILLNESS INDEX; SEX FACTORS; SMOKING; UNITED STATES;

EID: 84887880814     PISSN: 15412555     EISSN: 15412563     Source Type: Journal    
DOI: 10.3109/15412555.2013.844784     Document Type: Article

References (25)

1. Mapel DW, Roberts MH. New clinical insights into chronic obstructive pulmonary disease and their implications for pharmacoeconomic analyses. Pharmacoeconomics 2012;Oct 1; 30(10):869-85.
2. Fletcher MJ, Upton J, Taylor-Fishwick J, Buist SA, Jenkins C, Hutton J, et al. COPD uncovered: an international survey on the impact of chronic obstructive pulmonary disease [COPD] on a working age population. BMC Public Health 2011; 11:612.
3. Buist AS, McBurnie MA, Vollmer WM, Gillespier S, Burney P, Mannino DM, et al. BOLD Collaborative Research Group. International variation in the prevalence of COPD (The BOLD Study): a population-based prevalence study. Lancet 2007; 370:741-750.
4. Halbert RJ, Natoli JL, Gano A, Badamgarav E, Buist AS, Mannino DM. Global burden of COPD: systematic review and meta analysis. Eur Respir J 2006; 28(3):523-532.
5. Kessler R, Partridge MR, Miravitlles M, Cazzola M, Vogelmeier C, Leynaud D, Ostinelli J. Symptom variability in patients with severe COPD: a pan-European cross-sectional study. Eur Respir J 2011; 37:264-272.
6. GOLD PM. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management and prevention of chronic pulmonary disease, 2001. http://www.goldcopd.org/Guidelines/guidelines- resources.html
7. Vestbo J, Hurd SS, Agusti AG, Jones PW, Vogelmeier C, Anzueto A, et al. Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease, GOLD Executive Summary. Am J Respir Crit Care Med 2013; 187 (4):347-365.
8. Partridge MR, Karlsson N, Small IR. Patient insight into the impact of chronic obstructive pulmonary disease in the morning: an internet survey. Curr Med Res Opin 2009; 25(8):2043-2048.
9. Anderson P, Benford M, Harris N, Karavali M, Piercy J. Realworld physician and patient behaviour across countries: Disease-Specifi c Programmes-A means to understand. Curr Med Res Opin 2008; 24(11):3063-3072.
10. European Society for Opinion and Marketing Research (ESOMAR), International Code of Marketing and Social Research Practice 2007, http://www.icc.se/reklam/english/engresearch. pdf, accessed 22 August 2013.
11. U.S. Department of Health &Human Services, Summary of the HIPAA Privacy Rule Aug 2009, www.hhs.gov/ocr/privacy/index.html, accessed 22 August 2013.
12. Endicott J, Nee J, Harrison W, Blumenthal R. Quality of Life Enjoyment and Satisfaction Questionnaire: a new measure. Psycholpharmacol Bull 1993; 29:321-326.
13. Jones PW, Harding G, Berry P, Wiklund I, Chen WH, Kline Leidy N. Development and fi rst validation of the COPD Assessment Test. Eur Respir J 2009 Sep; 34(3):648-654.
14. StataCorp. 2011. Stata Statistical Software: Release 12. College Station, TX: StataCorp LP.
15. Damia ADD, Gimeno JC, Ferrer MJs, Fabregas ML, Folch PA, Paya JM. A study of the eff ect of proinfl ammatory cytokines on the epithelial cells of smokers, with or without COPD. Arch Bronconeumol 2011; 47(9):447-453.
16. Julian LJ, Gregorich SE, Earnest G, Eisner MD, Chen H, Blanc PD, et al. Screening for depression in chronic obstructive pulmonary disease. COPD 2009; 6(6):452-458.
17. Partridge MR, Schuermann W, Beckman O, Persson T, Polanowski T. Eff ect on lung function and morning activities of budesonide/formoterol versus salmeterol/fl uticasone in patients with COPD. Ther Adv Respir Dis 2009; 3(4);1-11.
18. Kerwin EM, DUrzo AD, Gelb AF, Lakkis H, Gil EG, Caracta CF. Efficacy and safety of a 12-week treatment with twice-daily aclidinium bromide in COPD patients (ACCORD COPD I). COPD 2012; 9:1-12.
19. DUrzo A, Ferguson GT, van Noord JA, Hirata K, Martin C, Horton R, et al. Efficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trial. Respiratory Res 2011; 12:156-159.
20. Kerwin E, Hebert J, Gallagher N, Martin C, Overend T, Alagappan VKT, Lu Y, Banerji D. Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 study. Eur Respir J 2012;40:1-10.
21. Beeh KM, Singh D, Di Scala L, Drollman A. Once-daily NVA237 improves exercise tolerance from the fi rst dose in patients with COPD: the GLOW3 trial. Int J COPD 2012; (7):503-513.
22. Liu XL, Tan JY, Wang T, Zhang Q, Zhang M, Mao LQ, Chen JX. Eff ectiveness of home-based pulmonary rehabilitation for patients with chronic obstructive pulmonary disease: a metaanalysis of randomised controlled trials. Rehabil Nurs Epub 2013/06/18.
23. Ramponi S, Tzani P, Aiello M, Marangio E, Clini E, Chetta A. Pulmonary rehabilitation improves cardiovascular response to exercise in COPD. Respiration Epub 2013/05/23.
24. Burgel PR, Nesme-Meyer P, Chanez P, Caillaud D, Carre P, Perez T, et al. Cough and sputum production are associated with frequent exacerbations and hospitalizations in COPD subjects. Chest 2009; 135(4):975-982.
25. Vestbo J, Prescott E, Lange P. Association of chronic mucus hypersecretion with FEV1 decline and chronic obstructive pulmonary disease morbidity. Copenhagen City Heart Study Group. Am J Respir Crit Care Med 1996; 153(5):1530-1535.